Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 140 clinical trials
Combination Therapy of RMC-4630 and LY3214996 in Metastatic KRAS Mutant Cancers (SHERPA)

This is a Phase I/Ib study in which the safety of the combination therapy of RMC-4630 and LY3214996 in the treatment of KRAS mutant cancers will be studied.

KRAS
pdac
  • 0 views
  • 15 Jun, 2022
  • 1 location
Binimetinib and Hydroxychloroquine in Treating Patients With KRAS Mutant Metastatic Pancreatic Cancer

This phase I trial studies the best dose of hydroxychloroquine when given together with binimetinib in treating patients with KRAS gene mutated pancreatic cancer that has spread to other places

  • 0 views
  • 04 Oct, 2022
  • 1 location
A Study of D3S-001 as Monotherapy in Subjects With Advanced Solid Tumors With a KRAS p.G12C Mutation

administered as monotherapy to subjects with advanced solid tumors with the Kirsten rat sarcoma viral oncogene homolog gene (KRAS) p.G12C mutation.

  • 0 views
  • 07 Oct, 2022
  • 1 location
Rigosertib Plus Nivolumab for KRAS+ NSCLC Patients Who Progressed on First-Line Treatment

A Phase1/2a Study of Rigosertib plus Nivolumab in Stage IV Lung Adenocarcinoma Patients with KRAS Mutation who Progressed on First-Line Treatment

rigosertib
measurable disease
tubal ligation
lung adenocarcinoma
nivolumab
  • 0 views
  • 24 Mar, 2022
  • 1 location
Mutant KRAS G12V-specific TCR Transduced T Cell Therapy for Advanced Pancreatic Cancer

This clinical trial will evaluate the safety and activity of mutant KRAS G12V-specific TCR transduced T cell therapy for advanced pancreatic cancer patients who express the KRAS G12V mutation

EGFR
cancer
monoclonal antibodies
NRAS
hepatitis b surface antigen
  • 64 views
  • 05 Jul, 2022
  • 1 location
JAB-21822 Activity in Adult Patients With Advanced Solid Tumors Harboring KRAS G12C Mutation

This study is to evaluate the safety and tolerability of JAB-21822 monotherapy and combination therapy in adult participants with advanced solid tumors harboring KRAS G12C mutation.

cetuximab
KRAS
EGFR
measurable disease
  • 0 views
  • 16 Sep, 2021
  • 4 locations
Mutant KRAS -Targeted Long Peptide Vaccine for Patients at High Risk of Developing Pancreatic Cancer

This Phase 1 study will evaluate safety and the immune response to pooled mutant-KRAS peptide vaccine with poly-ICLC adjuvant.

KRAS
BRCA2
Accepts healthy volunteers
palb2
BRCA1
  • 0 views
  • 24 Oct, 2022
  • 1 location
Evaluation of RMC-6236 in Subjects With Advanced Solid Tumors Harboring Specific Mutations in KRAS

Evaluate the safety and tolerability of RMC-6236 in adults with KRAS p.G12 mutant advanced solid tumors, KRAS p.G12C excluded.

KRAS
  • 0 views
  • 07 Oct, 2022
  • 10 locations
Phase 1b/2 Study of Futibatinib in Combination With Binimetinib in Patients With Advanced KRAS Mutant Cancer

Phase 1b/2 study to evaluate the FGFRi futibatinib in combination with the MEKi binimetinib in patients with advanced KRASmt tumors.

KRAS
measurable disease
  • 0 views
  • 13 Jun, 2022
  • 3 locations
MEK Inhibitor Combined With Anlotinib in the Treatment of KRAS-mutated Advanced Non-small Cell Lung Cancer

This is a Phase 1 exploratory study. The study plans to enroll 30 eligible patients to receive the MEK inhibitor trametinib (2 mg) in combination with anlotinib (8 mg, 10 mg, 12 mg). Patients participated in safety follow-up after the first course of treatment until 3 months after discontinuation due …

KRAS
lung carcinoma
  • 0 views
  • 22 Mar, 2022
  • 1 location